Our analysis demonstrates that treatment with ponatinib at an initial dose of 45 mg supports high response rates and survival outcomes among patients with CP‐CML resistant to 2G TKIs, regardless of BCR::ABL1 mutation status. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.